查詢結果分析
相關文獻
- Metformin 對肥胖孕婦體重控制的影響
- 運用多元策略提升孕婦初期子癲前症風險評估篩檢率
- Lung Cancer in Pregnancy: Report of Two Cases
- Anesthetic Management of a Parturient with Eisenmenger's Syndrome and Preeclampsia during Cesarean Section--A Case Report
- 大專學生體重控制教學設計
- Factors Affecting the Mortality of Sick Newborns Admitted to intensive Care Units
- 運動與體重控制
- 減重策略探討--以康寧護專體重控制班為例
- 協助一位不孕婦女子官切除後身體心像重建過程
- 運動與體重控制
頁籤選單縮合
題 名 | Metformin 對肥胖孕婦體重控制的影響=Effect of Metformin on Maternal Weight Control in Obese Pregnant Women: a Systematic Review and Meta-analysis |
---|---|
作 者 | 許晉瑜; 許艷玫; 李佳樺; 蔣清峻; 陳靜耀; | 書刊名 | 藥學雜誌 |
卷 期 | 33:3=132 2017.09[民106.09] |
頁 次 | 頁92-98 |
分類號 | 418.271 |
關鍵詞 | 孕婦; 體重控制; 子癲前症; Metformin; |
語 文 | 中文(Chinese) |
中文摘要 | 背景:目前研究發現體重過重或肥胖的懷孕婦女在妊娠期間發生併發症的風險較 高,對胎兒的生長和發育也可能造成影響,雖然妊娠期間飲食與運動的介入可減少體 重增加,但對併發症風險卻未明顯降低,因此本研究利用系統性回顧與統合分析的方 法期望確立 metformin 介入肥胖懷孕婦女的體重控制與對胎兒之影響。 方法:主要搜尋四種資料庫 (PUBMED、MEDLINE、Cochrane library 和 Embase) 進行系統性回顧,納入條件為懷孕12週以上、BMI 大於30 kg/m2、使用 metformin 和 測量相關結果的隨機對照試驗文獻,排除條件為對照組介入使用非安慰劑、有糖尿病 或多囊性卵巢症候群病史與無相關測量結果者,納入文獻使用 Cochrane risk of bias 評 估文獻品質,Revman 5.3.5進行統合分析,最後以森林圖呈現 metformin 對體重控制 效果、子癲前症發生率和胎兒出生體重 (Z-score) 之相關性。 結果:符合納入條件共兩篇文獻,統合分析的結果發現肥胖懷孕婦女使用 metformin 在懷孕期間的體重平均減少1.31公斤 (MD = -1.31, 95%CI -2.03 to -0.58),降 低了70%在妊娠期間發生子癲前症的風險 (RR = 0.30, 95%CI 0.15 to 0.63),並且對胎 兒體重無明顯的影響 (MD = -0.06, 95%CI -0.21 to 0.08)。 結論:Metformin 可降低肥胖懷孕婦女在妊娠期間的體重增加及發生子癲前症的 風險,且對胎兒的出生體重無明顯的降低,但由於目前相關研究數量仍然有限,未來 仍需進一步研究,才能對療效與安全性做更深入的探討。 |
英文摘要 | Background: Obese pregnant women are associated with increased risk for maternal and perinatal complications. Although some of studies found diet and exercise can help to decrease gestational weight gain, reduction for the risk of complication during pregnancy is unclear. We aimed to establish whether metformin improves maternal weight control and fetal outcome in obese pregnant women. Method: We searched PUBMED, MEDLINE, Cochrane and EMBASE up to Nov 2016. Inclusion criteria that participant were obese pregnant women over 12 weeks gestation who had BMI 30 kg/m2 or more, metformin use and randomized controlled trial with relevant measured outcomes. Exclusion criteria were a diagnosis of diabetes or polycystic ovarian syndrome. The quality of studies was evaluated by use of Cochrane risk of bias tool. Rev man 5.3.5 was used to analyze data. Results about the effect of metformin on weight control, the risk of preeclampsia and perinatal birth weight were presented by the forest plot. Result: Two RCTs involving 899 participants met the inclusion criteria. Our results indicated a significant decrease in gestational weight (MD = -1.31, 95%CI -2.03 to -0.58) with metformin compared to placebo. The risk of preeclampsia also declined significantly in participant receiving metformin (RR = 0.30, 95%CI 0.15 to 0.63). However, there was no significant difference between the two groups for the neonatal birth-weight z score (MD = -0.06, 95%CI -0.21 to 0.08). Conclusion: The available evidence suggests effects of metformin in decrease of the gestational weight gain and the risk of preeclampsia in obese women but not affecting neonatal birth weight. However, we still need more research to answer the safety of using metformin in obese women during pregnancy in the future. |
本系統中英文摘要資訊取自各篇刊載內容。